For some opioid makers, the financial outlook is painful.

Between falling prices for many of the medicines and fast-growing litigation, a few of these companies have only modest flexibility to cope with these mounting risks, according to a new analysis by Moody’s Investor Service. And the drug maker most likely to be impacted is Endo International (ENDP).

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

    • Hi Gaurav,
      The report is called ‘Drug manufacturers and distributors face rising risks related to the US opioid crisis’ and was released on Nov. 30.
      ed at Pharmalot

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy